Chargement en cours...
ACTR-56. PHASE II TRIAL OF NILOTINIB IN PDGFR-ALPHA ENRICHED RECURRENT GLIOBLASTOMA
BACKGROUND: This phase II study was designed to determine the efficacy of nilotinib in a biomarker-selected population of recurrent glioblastoma (GBM), enriched for platelet-derived growth factor receptor-alpha (PDGFR-alpha) activation. Nilotinib is a multi-kinase inhibitor approved as treatment for...
Enregistré dans:
| Publié dans: | Neuro Oncol |
|---|---|
| Auteurs principaux: | , , |
| Format: | Artigo |
| Langue: | Inglês |
| Publié: |
Oxford University Press
2019
|
| Sujets: | |
| Accès en ligne: | https://ncbi.nlm.nih.gov/pmc/articles/PMC6846918/ https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1093/neuonc/noz175.098 |
| Tags: |
Ajouter un tag
Pas de tags, Soyez le premier à ajouter un tag!
|